Bioprocessing Trends: Annual Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bioprocessing Trends: Annual Survey
Results from our annual survey. This article contains online bonus material and is part of a special issue on Bioprocessing and Sterile Manufacturing.


Pharmaceutical Technology
Volume 35, pp. s6

Equipment


Table I: What is (are) the greatest advantages to disposable equipment? (Multiple answers allowed)
The debate continues over the use of disposables in biopharmaceutical manufacturing, with firms considering the convenience, cost, and the environmental impact of single-use, largely plastic, components. Anecdotally, it seems the industry is increasingly embracing disposable components. Yet our survey indicates an insignificant increase in the number of respondents using all-disposable systems—9% this year versus 8% last. Hybrid systems, which combine stainless and disposable components, remains the most popular choice, but the 66% of respondents using hybrid systems represents a notable decline from last year's 72%, which was down from the previous year's 74%. The use of stainless components continues to rise—26% of respondents this year report using all stainless equipment, an increase over last year's 20%. Interestingly, 11% of respondents who now use hybrid systems say they plan to convert to fully disposable equipment in the coming year, while no respondents anticipate moving to an all-stainless system. No companies with revenues above $5 billion use completely disposable systems; 88% of respondents from companies with revenues in excess of $50 billion use hybrid systems.

As in years past, we detected some marked differences in perceived advantages and challenges with disposable equipment among users of that equipment versus non-users. The first discrepancy arises over the question of cost savings. Thirty-five percent of all-stainless users (and 31% of hybrid users) believe there's a cost advantage to all-disposable systems. In contrast, 54% of all-disposable users say cost is an advantage to all-disposable systems, suggesting users of the other two systems underestimate the savings to be gained by an all-disposable system. Those who use all-disposable systems also perceive disposables to be more environmentally friendly (23%) than do all-stainless users (15%) and hybrid users (10%). All-stainless users also underestimate process consistency that can be achieved with all-disposable equipment, as only 18% of stainless users cite this as an advantage, contrasted with 31%, who actually use all-disposable systems. Additional responses suggest it may be easier to incorporate automation and may have greater regulatory acceptance than all stainless users might think.


Table II: What is (are) the greatest challenges to disposable equipment? (Multiple answers allowed)
These same discrepancies arise when respondents were asked about the challenges inherent in single-use technologies. Users of all-stainless equipment overestimated the cost, risk of contamination, and process inconsistency, compared with respondents who use all-disposable equipment. On the other hand, all-stainless users underestimated the difficulty of incorporating process analytical technologies, implementing QbD principles, and the risk posed by extractables and leachables. In addition, users of hybrid technologies reported having greater challenges gaining regulatory acceptance (12.4%) than did users of all-disposable equipment, none of whom (0%) reported this as a challenge.

Outsourcing

The percentage of respondents who say their companies outsource the manufacture of biologics rose again slightly this year over last year (36% this year versus 33% last), which represented a small rise over the previous year (30%). The reasons for outsourcing seemed to have changed slightly from last year's reasons. This year, 51% of respondents say their companies outsource to compensate for no or limited manufacturing capacity, whereas only 45% gave this reason last year. The percentage citing cost effectiveness climbed this year, to 49%, up from 41% last year. Companies with revenues under $10 billion are most likely to outsource, and their reasons for doing so differ, as well. A greater percentage of respondents from companies with revenues under $5 billion outsource because they have no or limited manufacturing capacity (for example, 71% of respondents from companies with revenues between $1 billion and $5 billion give this as the reason). Companies with revenues greater than $5 billion outsource to realize cost savings. Smaller companies—those with revenues under $500 million also say they lack the expertise internally (up to 75% of respondents from companies with revenues under $250 million, as opposed to 33% from companies with revenues between $5 billion and $10 billion).


Table III: Challenges according to protein class.
Overall, 61% of respondents say they outsource the manufacture of clinical-trial materials, and 49% said they outsource the manufacture of both drug substance (APIs) and finished drug product. Thirty-three percent outsource the manufacture of drug substance only, and an equal percentage (31%) said they outsource process development and full commercial-scale manufacture. The functions least likely to be outsourced were drug product only, and formulation development (29% each). There were no clear-cut patterns when it came to the size of companies and the functions they outsourced. In general, companies with revenues under $500 million were more likely to outsource process and formulation development, than were companies with larger revenues. Whereas companies with revenues above $500 million were more likely to outsource the manufacture of both drug substance and drug product than were smaller companies.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here